Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin + rituximab versus investigator's choice therapy in relapsed or refractory CD22-positive aggressive non-Hodgkin lymphoma
2010-020147-12Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of inotuzumab ozogamicin and rituximab in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Pfizer. Primary endpoint: Overall survival. Started Nov 2010; status: completed.
02
Drugs
inotuzumab ozogamicinrituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2010-020147-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020147-12.